<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03305341</url>
  </required_header>
  <id_info>
    <org_study_id>NDA215163</org_study_id>
    <secondary_id>FWA00015357</secondary_id>
    <secondary_id>IRB00009424</secondary_id>
    <secondary_id>IORG0007849</secondary_id>
    <secondary_id>IND152006</secondary_id>
    <secondary_id>NDA215163</secondary_id>
    <secondary_id>BLA761200</secondary_id>
    <nct_id>NCT03305341</nct_id>
  </id_info>
  <brief_title>Discovery Stage (Proof-of-concept) COVID-19 Antigen Presentation Therapeutic Vaccine</brief_title>
  <acronym>COVID-19--AP</acronym>
  <official_title>Conducting an Initial Small, Controlled Clinical Trial to Assess for Therapeutic Vaccine Activity (Proof-of-concept) That Suggests the Potential for Clinical Benefits of COVID-19 Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicine Invention Design, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Conducting an initial small, controlled clinical trial to assess for therapeutic vaccine
      activity (proof-of-concept) that suggests the potential for clinical benefit of COVID-19
      patients.

        1. Treat Infection of Multiple Gene Mutation COVID-19 Virus Strains.

        2. Activate Antigen Presentation Reaction to COVID-19 Specific Antigen.

        3. Produce Antigen Presentation Memory to COVID-19 Specific Antigen.

        4. Produce Trained Immunity to COVID-19 Specific Antigen.

        5. Avoid Antibody-Dependent Enhancement to COVID-19 Virus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Conducting an initial small, controlled trial to assess for therapeutic vaccine activity
           (proof-of-concept) that suggests the potential for clinical benefit of COVID-19
           patients.

        -  20 Moderate COVID-19 patients

        -  Moderate COVID-19

        -  Positive testing by standard RT-PCR assay or equivalent testing

        -  Symptoms of moderate illness with COVID-19, which could include any symptom of mild
           illness or shortness of breath with exertion

        -  Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate ≥
           20 breaths per minute, saturation of oxygen (SpO2) &gt; 93% on room air at sea level, heart
           rate ≥ 90 beats per minute

        -  No clinical signs indicative of Severe or Critical Illness Severity

        -  Our trial duration will be 4-week duration.

        -  0.1mg / 0.5 ml Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection

        -  Intradermic Injection, ID

        -  After 60 hours

        -  Test Macrophage Migration Inhibitory Factor (MMIF)

        -  If Macrophage Migration Inhibitory Factor (MMIF) is positive (+)

        -  Successful trained immunity to COVID-19 specific antigen
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 18, 2020</start_date>
  <completion_date type="Anticipated">November 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Macrophage Migration Inhibitory Factor (MMIF)</measure>
    <time_frame>Duration at least 28 days</time_frame>
    <description>Macrophage Migration Inhibitory Factor (MMIF), assessed by ELISA Sandwich Kit</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Assess for therapeutic vaccine activity (proof-of-concept)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1mg Nucleocapsid-GM-CSF Protein
0.5 ml Lactated Ringer's Injection, USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Therapeutic Vaccine - Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection</intervention_name>
    <description>Intradermic Injection, ID
COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection</description>
    <arm_group_label>Assess for therapeutic vaccine activity (proof-of-concept)</arm_group_label>
    <other_name>COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Conducting an initial small, controlled trial to assess for therapeutic vaccine
             activity (proof-of-concept) that suggests the potential for clinical benefit of
             COVID-19 patients.

          -  20 Moderate COVID-19 patients

        Inclusion Criteria:

          -  Moderate COVID-19

          -  Positive testing by standard RT-PCR assay or equivalent testing

          -  Symptoms of moderate illness with COVID-19, which could include any symptom of mild
             illness or shortness of breath with exertion

          -  Clinical signs suggestive of moderate illness with COVID-19, such as respiratory rate
             ≥ 20 breaths per minute, saturation of oxygen (SpO2) &gt; 93% on room air at sea level,
             heart rate ≥ 90 beats per minute

          -  No clinical signs indicative of Severe or Critical Illness Severity

        Exclusion Criteria:

          -  1. Severe or Critical Illness Severity

          -  2. Pregnancy

          -  3. Breast-feeding

          -  4. The patients with other serious inter-current illness

          -  5. Serious Allergy

          -  6. Serious Bleed Tendency

          -  7. The prohibition of the biological product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HAN XU, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Medicine Invention Design, Inc. (MIDI) - IORG0007849</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HAN XU, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medicine Invention Design, Inc. (MIDI) - IORG0007849</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HAN XU, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicine Invention Design, Inc. (MIDI) - IORG0007849</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicine Invention Design Incorporation (MIDI) - IORG0007849</name>
      <address>
        <city>North Bethesda</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ohrp.cit.nih.gov/search</url>
    <description>FWA00015357</description>
  </link>
  <link>
    <url>http://ohrp.cit.nih.gov/search</url>
    <description>IRB00009424</description>
  </link>
  <link>
    <url>http://ohrp.cit.nih.gov/search</url>
    <description>IORG0007849</description>
  </link>
  <reference>
    <citation>Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O'Neill LA, Xavier RJ. Trained immunity: A program of innate immune memory in health and disease. Science. 2016 Apr 22;352(6284):aaf1098. doi: 10.1126/science.aaf1098. Epub 2016 Apr 21. Review.</citation>
    <PMID>27102489</PMID>
  </reference>
  <reference>
    <citation>Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. Nat Rev Immunol. 2020 Jun;20(6):375-388. doi: 10.1038/s41577-020-0285-6. Epub 2020 Mar 4. Review.</citation>
    <PMID>32132681</PMID>
  </reference>
  <reference>
    <citation>Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained Immunity-Based Vaccines: A New Paradigm for the Development of Broad-Spectrum Anti-infectious Formulations. Front Immunol. 2018 Dec 17;9:2936. doi: 10.3389/fimmu.2018.02936. eCollection 2018. Review.</citation>
    <PMID>30619296</PMID>
  </reference>
  <reference>
    <citation>Guevara-Hoyer K, Saz-Leal P, Diez-Rivero CM, Ochoa-Grullón J, Fernández-Arquero M, Pérez de Diego R, Sánchez-Ramón S. Trained Immunity Based-Vaccines as a Prophylactic Strategy in Common Variable Immunodeficiency. A Proof of Concept Study. Biomedicines. 2020 Jul 9;8(7). pii: E203. doi: 10.3390/biomedicines8070203.</citation>
    <PMID>32660100</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 4, 2017</study_first_submitted>
  <study_first_submitted_qc>October 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2017</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medicine Invention Design, Inc</investigator_affiliation>
    <investigator_full_name>Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair</investigator_full_name>
    <investigator_title>M.D., Ph.D., Sponsor-Investigator, IORG Director, Monitor, IRB Chair</investigator_title>
  </responsible_party>
  <keyword>Escape Mutation</keyword>
  <keyword>ADE</keyword>
  <keyword>Antigen Presentation</keyword>
  <keyword>APC</keyword>
  <keyword>Trained Immunity</keyword>
  <keyword>Nucleocapsid</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>innate immune memory</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Molgramostim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

